CPT code 96411 denotes an add-on chemotherapy administration using an intravenous push technique for each additional drug given during a chemotherapy encounter. Nationally, this code matters because precise coding of multi-drug chemotherapy sessions affects clinical documentation, billing clarity, and accurate capture of services for payers and Medicare. Correct use ensures each additional agent is represented on the claim and supports appropriate payment and utilization tracking.

Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 96411, typical sites of service, common modifiers associated with oncology billing, and how this add-on code interacts with primary chemotherapy administration codes. The publication outlines benchmarks and payer coverage patterns where available, highlights relevant coding practice considerations, and summarizes policy updates affecting chemotherapy administration coding nationally.

The intended audience includes billing professionals, oncology practice managers, compliance officers, and policy analysts seeking a clear, national-level reference for reporting add-on intravenous push chemotherapy drugs with CPT code 96411.